The DOI matches its Crossref record.
β-Arrestin links endothelin A receptor to β-catenin signaling to induce ovarian cancer cell invasion and metastasis
Open accessAbstract
The activation of endothelin-A receptor (ET A R) by endothelin-1 (ET-1) has a critical role in ovarian tumorigenesis and progression. To define the molecular mechanism in ET-1-induced tumor invasion and metastasis, we focused on β-arrestins as scaffold and signaling proteins of G protein-coupled receptors. Here, we demonstrate that, in ovarian cancer cells, β-arrestin is recruited to ET A R to form two trimeric complexes: one through the interaction with Src leading to epithelial growth factor receptor (EGFR) transactivation and β-catenin Tyr phosphorylation, and the second through the physical association with axin, contributing to release and inactivation of glycogen synthase kinase (GSK)-3β and β-catenin stabilization. The engagement of β-arrestin in these two signaling complexes concurs to activate β-catenin signaling pathways. We then demonstrate that silencing of both β-arrestin-1 and β-arrestin-2 inhibits ET A R-driven signaling, causing suppression of Src, mitogen-activated protein kinase (MAPK), AKT activation, as well as EGFR transactivation and a complete inhibition of ET-1-induced β-catenin/TCF transcriptional activity and cell invasion. ET A R blockade with the specific ET A R antagonist ZD4054 abrogates the engagement of β-arrestin in the interplay between ET A R and the β-catenin pathway in the invasive program. Finally, ET A R is expressed in 85% of human ovarian cancers and is preferentially co-expressed with β-arrestin-1 in the advanced tumors. In a xenograft model of ovarian metastasis, HEY cancer cells expressing β-arrestin-1 mutant metastasize at a reduced rate, highlighting the importance of this molecule in promoting metastases. ZD4054 treatment significantly inhibits metastases, suggesting that specific ET A R antagonists, by disabling multiple signaling activated by ET A R/β-arrestin, may represent new therapeutic opportunities for ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Teaching old receptors new tricks: biasing seven-transmembrane receptors
Rajagopal, S., Rajagopal, K., & Lefkowitz, R. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3024 · Cited by 825
Davenport, A. P., Hyndman, K. A., Dhaun, N., Southan, C., Kohan, D. E., Pollock, J. S., Pollock, D. M., Webb, D. J., & Maguire, J. J. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011833 · Cited by 772
Therapeutic potential of β-arrestin- and G protein-biased agonists
Whalen, E. J., Rajagopal, S., & Lefkowitz, R. J. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.11.004 · Cited by 510
The Diverse Roles of Arrestin Scaffolds in G Protein–Coupled Receptor Signaling
Peterson, Y. K., & Luttrell, L. M. (2017) · Pharmacological Reviews · doi:10.1124/pr.116.013367 · Cited by 422
Beyond Desensitization: Physiological Relevance of Arrestin-Dependent Signaling
Luttrell, L. M., Gesty-Palmer, D., & Sibley, D. R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002436 · Cited by 369
Endothelin 1 in cancer: biological implications and therapeutic opportunities
Rosanò, L., Spinella, F., & Bagnato, A. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3546 · Cited by 348
Self-citationG Protein–Coupled Receptor Signaling Through β-Arrestin–Dependent Mechanisms
Jean-Charles, P.-Y., Kaur, S., & Shenoy, S. K. (2017) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000482 · Cited by 280
Role of the endothelin axis and its antagonists in the treatment of cancer
Bagnato, A., Loizidou, M., Pflug, B., Curwen, J., & Growcott, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01217.x · Cited by 107
Self-citationYuen, T. J., Johnson, K. R., Miron, V. E., Zhao, C., Quandt, J., Harrisingh, M. C., Swire, M., Williams, A., McFarland, H. F., Franklin, R. J. M., et al. (2013) · Brain · doi:10.1093/brain/awt024 · Cited by 80
“Both are G protein coupled receptors, but their association with different sets of G proteins results in their activation of separate downstream signalling pathways, for example, ET-A promotes vasoconstriction whereas ET-B can promote vasodilation (Aramori and Nakanishi, 1992; Rosano et al., 2009; Kawanabe and Nauli,…”
BackgroundSrc family kinases and paclitaxel sensitivity
Le, X.-F., & Bast, Jr. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.4.16430 · Cited by 79
Essential requirement for β-arrestin2 in mouse intestinal tumors with elevated Wnt signaling
Bonnans, C., Flacelière, M., Grillet, F., Dantec, C., Desvignes, J.-P., Pannequin, J., Severac, D., Dubois, E., Bibeau, F., Escriou, V., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109457109 · Cited by 49
Metadata
- Authors
- Rosanò, L., Cianfrocca, R., Masi, S., Spinella, F., Di Castro, V., Biroccio, A., Salvati, E., Nicotra, M. R., Natali, P. G., & Bagnato, A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2009-02-24
- Volume
- 106
- Issue
- 8
- Pages
- 2806-2811
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2037276555
- Cited by
- 164
- References
- 0
- FWCI
- 6.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.